The effect of combination therapy with erythropoietin and methylprednisolone in patients with traumatic cervical spinal cord injury: a pilot randomized controlled trial.
Journal
Spinal cord
ISSN: 1476-5624
Titre abrégé: Spinal Cord
Pays: England
ID NLM: 9609749
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
01
06
2020
accepted:
01
12
2020
revised:
01
12
2020
pubmed:
27
1
2021
medline:
16
10
2021
entrez:
26
1
2021
Statut:
ppublish
Résumé
Pilot double-blinded randomized controlled trial. To investigate the additive effect of recombinant human erythropoietin (rhEPO) on functional outcome and disability in patients with traumatic cervical spinal cord injury (TCSCI). University-affiliated hospital in Mashhad, Iran. Patients with acute TCSCI admitted within 8 h after injury were randomly assigned to receive only methylprednisolone (M group) or rhEPO 500 IU/mL plus methylprednisolone (M + E group). All the patients underwent surgery within the next several days. Neurological function was assessed on admission, and at 6th and 12th months after the injury according to the sphincter function and American spinal cord injury association (ASIA) scale. Overall, 54 patients (mean age: 39.7 ± 13.3 years) including 46 (85%) males were studied in two groups of 27. The likelihood of developing adverse neurological outcomes (ASIA impairment score of A compared to D or E) was not significantly different between the groups after 6 (OR = 0.39, 95% CI = 0.03-4.80, P = 0.46) and 12 months (OR = 0.83, 95% CI = 0.11-6.11, P = 0.86). The groups also showed no significant difference in 1-year mortality (OR = 0.83, 95% CI = 0.25-2.74, P = 0.76). It is not clear whether combination therapy with erythropoietin compared to methylprednisolone alone improves neurological functions of patients with TCSCI. Our study provides interim data to guide future larger definitive trials.
Identifiants
pubmed: 33495576
doi: 10.1038/s41393-020-00604-2
pii: 10.1038/s41393-020-00604-2
doi:
Substances chimiques
Erythropoietin
11096-26-7
Methylprednisolone
X4W7ZR7023
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
347-353Subventions
Organisme : Mashhad University of Medical Sciences (MUMS)
ID : 921030
Références
Lee B, Cripps R, Fitzharris M, Wing P. The global map for traumatic spinal cord injury epidemiology: update 2011, global incidence rate. Spinal Cord. 2014;52:110.
doi: 10.1038/sc.2012.158
Cripps R, Lee B, Wing P, Weerts E, Mackay J, Brown D. A global map for traumatic spinal cord injury epidemiology: towards a living data repository for injury prevention. Spinal Cord. 2011;49:493.
doi: 10.1038/sc.2010.146
Devivo M. Epidemiology of traumatic spinal cord injury: trends and future implications. Spinal Cord. 2012;50:365.
doi: 10.1038/sc.2011.178
Sekhon LH, Fehlings MG. Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine. 2001;26:S2–12.
doi: 10.1097/00007632-200112151-00002
Oyinbo CA. Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade. Acta Neurobiol Exp. 2011;71:281–99.
Rowland JW, Hawryluk GW, Kwon B, Fehlings MG. Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg Focus. 2008;25:E2.
doi: 10.3171/FOC.2008.25.11.E2
Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, et al. Administration of methylprednisolone for 24 or 48 h or tirilazad mesylate for 48 h in the treatment of acute spinal cord injury: results of the third national acute spinal cord injury randomized controlled trial. JAMA. 1997;277:1597–604.
doi: 10.1001/jama.1997.03540440031029
Huang H, Young W, Skaper S, Chen L, Moviglia G, Saberi H, et al. Clinical neurorestorative therapeutic guidelines for spinal cord injury (IANR/CANR version 2019). J Orthop Transl. 2020;20:14–24.
Celik M, Gökmen N, Erbayraktar S, Akhisaroglu M, Konakç S, Ulukus C, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA. 2002;99:2258–63.
doi: 10.1073/pnas.042693799
Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA. 2002;99:9450–5.
doi: 10.1073/pnas.142287899
Grasso G, Sfacteria A, Passalacqua M, Morabito A, Buemi M, Macrì B, et al. Erythropoietin and erythropoietin receptor expression after experimental spinal cord injury encourages therapy by exogenous erythropoietin. Neurosurgery. 2005;56:821–7.
doi: 10.1227/01.NEU.0000156493.00904.7E
Matis GK, Birbilis TA. Erythropoietin in spinal cord injury. Eur Spine J. 2009;18:314.
doi: 10.1007/s00586-008-0829-0
Kaptanoglu E, Solaroglu I, Okutan O, Surucu HS, Akbiyik F, Beskonakli E. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings. Neurosurg Rev. 2004;27:113–20.
doi: 10.1007/s10143-003-0300-y
Wilson JR, Forgione N, Fehlings MG. Emerging therapies for acute traumatic spinal cord injury. Can Med Assoc J. 2013;185:485–92.
doi: 10.1503/cmaj.121206
Gorio A, Madaschi L, Di Stefano B, Carelli S, Di Giulio AM, De, et al. Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. Proc Natl Acad Sci USA. 2005;102:16379–84.
doi: 10.1073/pnas.0508479102
Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016;25:1057–73.
doi: 10.1177/0962280215588241
Cerri G, Montagna M, Madaschi L, Merli D, Borroni P, Baldissera F, et al. Erythropoietin effect on sensorimotor recovery after contusive spinal cord injury: an electrophysiological study in rats. Neuroscience. 2012;219:290–301.
doi: 10.1016/j.neuroscience.2012.05.041
Chen G, Shi JX, Hang CH, Xie W, Liu J, Liu X. Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO). Neurosci Lett. 2007;425:177–82.
doi: 10.1016/j.neulet.2007.08.022
Yatsiv I, Grigoriadis N, Simeonidou C, Stahel PF, Schmidt OI, Alexandrovitch A, et al. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J. 2005;19:1701–3.
doi: 10.1096/fj.05-3907fje
Kontogeorgakos VA, Voulgaris S, Korompilias AV, Vekris M, Polyzoidis KS, Bourantas K, et al. The efficacy of erythropoietin on acute spinal cord injury. An experimental study 346 on a rat model. Arch Orthop Trauma Surg. 2009;129:189–94.
doi: 10.1007/s00402-008-0594-x
Özdemir B, Batçık E, Ayçiçek E, Canaz G, Akdemir O, Alataş İ et al. Investigation of dose-dependent neuroprotective effect of human recombinant erythropoietin in acute spinal cord injury induced rats. Int J Clin Exp Med. 2016;9:6385–93.
Grasso G, Sfacteria A, Meli F, Fodale V, Buemi M, Iacopino DG. Neuroprotection by erythropoietin administration after experimental traumatic brain injury. Brain Res. 2007;1182:99–105.
doi: 10.1016/j.brainres.2007.08.078
Çetin A, Nas K, Büyükbayram H, Ceviz A, Ölmez G. The effects of systemically administered methylprednisolone and recombinant human erythropoietin after acute spinal cord compressive injury in rats. Eur Spine J. 2006;15:1539–44.
doi: 10.1007/s00586-006-0091-2
Xiong M, Chen S, Yu H, Liu Z, Zeng Y, Li F. Neuroprotection of erythropoietin and methylprednisolone against spinal cord ischemia-reperfusion injury. J Huazhong Univ Sci Technol. 2011;31:652.
doi: 10.1007/s11596-011-0576-z
Dalla Costa D, Beghi E, Carignano P, Pagliacci C, Faccioli F, Pupillo E, et al. Tolerability and efficacy of erythropoietin (EPO) treatment in traumatic spinal cord injury: a preliminary randomized comparative trial vs. methylprednisolone (MP). Neurological Sci. 2015;36:1567–74.
doi: 10.1007/s10072-015-2182-5
Nekoui A, Tresierra VD, Abdolmohammadi S, Shedid D, Blaise G. Neuroprotective effect of erythropoietin in postoperation cervical spinal cord injury: case report and review. Anesth Pain Med. 2015;5:e28849.
doi: 10.5812/aapm.28849
Alibai EA, Baghban F, Farrokhi MR, Mohebali N, Ashraf MH. Effects of human erythropoietin on functional outcome of patients with traumatic cervical cord injury; a pilot randomized clinical trial. Bull Emerg Trauma. 2015;3:79.
pubmed: 27162908
pmcid: 4771246
Yazihan N, Uzuner K, Salman B, Vural M, Koken T, Arslantas A. Erythropoietin improves oxidative stress following spinal cord trauma in rats. Injury. 2008;39:1408–13.
doi: 10.1016/j.injury.2008.03.010